1. Home
  2. TSI vs SERA Comparison

TSI vs SERA Comparison

Compare TSI & SERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TCW Strategic Income Fund Inc.

TSI

TCW Strategic Income Fund Inc.

HOLD

Current Price

$4.94

Market Cap

234.6M

Sector

Finance

ML Signal

HOLD

Logo Sera Prognostics Inc.

SERA

Sera Prognostics Inc.

HOLD

Current Price

$2.83

Market Cap

130.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TSI
SERA
Founded
1987
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Precision Instruments
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
234.6M
130.5M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
TSI
SERA
Price
$4.94
$2.83
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
106.8K
62.9K
Earning Date
01-01-0001
11-13-2025
Dividend Yield
7.46%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$95,000.00
Revenue This Year
N/A
$25.84
Revenue Next Year
N/A
$347.37
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1.06
52 Week Low
$4.48
$1.37
52 Week High
$4.87
$8.73

Technical Indicators

Market Signals
Indicator
TSI
SERA
Relative Strength Index (RSI) 41.93 38.04
Support Level $4.84 $2.80
Resistance Level $4.96 $3.67
Average True Range (ATR) 0.04 0.26
MACD -0.00 -0.08
Stochastic Oscillator 42.93 14.14

Price Performance

Historical Comparison
TSI
SERA

About TSI TCW Strategic Income Fund Inc.

Tcw Strategic Income Fund Inc operates as a closed-end management investment company. Its investment objective is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as airlines, banks, beverages, biotechnology, chemicals, computers, diversified financial services, entertainment and others.

About SERA Sera Prognostics Inc.

Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.

Share on Social Networks: